<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03431415</url>
  </required_header>
  <id_info>
    <org_study_id>RAXSIA</org_study_id>
    <nct_id>NCT03431415</nct_id>
  </id_info>
  <brief_title>Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer</brief_title>
  <acronym>RAXSIA</acronym>
  <official_title>Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut universitaire de cardiologie et de pneumologie de Québec, University Laval</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is disease free survival rate at 5 years in stage IA2&#xD;
      (T1aN0M0 or T1bN0M0 only) non-small cell lung cancer (NSCLC) patients treated either by&#xD;
      surgery or stereotactic body radiation therapy (SBRT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Today, the best medical literature available confirms that surgery is superior to radiation&#xD;
      therapy in the treatment of the early stage lung cancer. However, good emerging data&#xD;
      demonstrates potential equality between these two treatments. Two major international studies&#xD;
      have tried to compare both treatments but have failed to complete the study because of the&#xD;
      lack of patients accrual. We chose to design a trial in which patients will be part of a&#xD;
      shared decision making process in selecting the treatment modality.&#xD;
&#xD;
      Patients with early stage lung cancer, that can undergo surgical treatment will be offered&#xD;
      SBRT, and in conjunction with the pulmonologist will decide which treatment they prefer. We&#xD;
      intend to complete the recruitment of patients within 02 years, then follow-up for 5 more&#xD;
      years to collect data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Accrual issues&#xD;
  </why_stopped>
  <start_date type="Actual">January 28, 2018</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
    <description>To compare the disease free survival of patients with Stage up to IA2 (T1aN0M0 or T1bN0M0) NSCLC managed either by SBRT or surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival rate at 5 years in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of morbidity</measure>
    <time_frame>5 years</time_frame>
    <description>Level of morbidity in both arms (CTCAE 4.0 - common toxicity criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of efficacy in the SBRT arm</measure>
    <time_frame>5 years</time_frame>
    <description>Level of efficacy in the SBRT arm (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL assessment</measure>
    <time_frame>5 years</time_frame>
    <description>QOL assessment with SF36 questionnaire (pre and post treatment) in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 and DLCO decline at 1-year post-treatment in both arms</measure>
    <time_frame>1 year</time_frame>
    <description>FEV1 or DLCO decline at 1-year post-treatment in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic evaluation in both arms</measure>
    <time_frame>5 years</time_frame>
    <description>Health economic evaluation in both arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non-small Cell Lung Cancer Stage I</condition>
  <condition>Surgery</condition>
  <condition>Stereotactic Body Radiation Therapy</condition>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients that will undergo surgery (anatomical segmentectomy, lobectomy or bilobectomy) as primary lung cancer treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT (Stereotactic Body Radiation Therapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients that will undergo SBRT as primary lung cancer treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anatomical Segmentectomy, Lobectomy or Bilobectomy</intervention_name>
    <description>Lung Cancer Anatomical Resection</description>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy</intervention_name>
    <description>SBRT treatment. 48Gy in 4 sessions for peripheral lesions and 50Gy in 5 sessions for central lesions.</description>
    <arm_group_label>SBRT (Stereotactic Body Radiation Therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18-75&#xD;
&#xD;
          -  Pathologically (histologically or cytologically) proven NSCLC.&#xD;
&#xD;
          -  Stage IA2 T1aN0M0 or T1bN0M0 only, fit for surgery.&#xD;
&#xD;
               -  Tumor ≤ 2 cm (T1a or T1b according to AJCC, 8th ed.)&#xD;
&#xD;
          -  Hilar or mediastinal lymph nodes ≤ 1 cm with no abnormal hilar or mediastinal uptake&#xD;
             on PET scan are considered N0.&#xD;
&#xD;
               -  Patients with hilar or mediastinal lymph nodes &gt; 1 cm on CT scan or abnormal PET&#xD;
                  scan (including suspicious but non-diagnostic uptake) are eligible, provided&#xD;
                  directed tissue biopsies by EBUS or mediastinoscopy of all abnormally identified&#xD;
                  areas are negative for cancer.&#xD;
&#xD;
               -  EBUS preferable&#xD;
&#xD;
               -  No regional or distant metastases.&#xD;
&#xD;
          -  Resectable disease and treatable by SBRT&#xD;
&#xD;
          -  Peripherally located tumor.&#xD;
&#xD;
               -  Primary tumor within or touching the zone of the proximal bronchial tree, defined&#xD;
                  as a volume of 2 cm in all directions around the proximal bronchial tree are&#xD;
                  excluded (carina, right and left main bronchi, right and left upper lobe bronchi,&#xD;
                  intermedius bronchus, right middle lobe bronchus, lingular bronchus, right and&#xD;
                  left lower lobe bronchi).&#xD;
&#xD;
               -  No involvement of the central pleura and/or structures of the mediastinum.&#xD;
&#xD;
          -  Staging studies must be done within 8 weeks prior to study entry&#xD;
&#xD;
          -  Patients must provide study specific informed consent prior to study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously operated lung cancer.&#xD;
&#xD;
          -  Previous thoracic irradiation.&#xD;
&#xD;
          -  Patients with a history of other malignancies, except: adequately treated non-melanoma&#xD;
             skin cancer, curatively treated in-situ cancer, or other solid tumors curatively&#xD;
             treated with no evidence of disease for ≥ 5 years following the end of treatment and&#xD;
             which, in the opinion of the treating physician, do not have a substantial risk of&#xD;
             recurrence of the prior malignancy.&#xD;
&#xD;
          -  Pulmonary nodule manifested as pure ground-glass opacity.&#xD;
&#xD;
          -  Severe pulmonary hypertension.&#xD;
&#xD;
          -  Severe cardiac, hepatic or renal insufficiency.&#xD;
&#xD;
          -  Severe peripheral vascular disease.&#xD;
&#xD;
          -  Severe cerebral or psychiatric pathologies.&#xD;
&#xD;
          -  Severe chronic heart disease.&#xD;
&#xD;
          -  Life expectancy &lt; 6 months.&#xD;
&#xD;
          -  Pregnant or lactating woman.&#xD;
&#xD;
          -  Unwilling to have follow-up.&#xD;
&#xD;
          -  Central tumor where pneumonectomy might be considered.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula A Ugalde Figueroa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor, Thoracic Surgeon, Research Coordinator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôtel-Dieu de Québec (CHUQ)</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1R2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Quebec - Université Laval</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 28, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</investigator_affiliation>
    <investigator_full_name>Paula Antonia Ugalde Figueroa</investigator_full_name>
    <investigator_title>Research Coordinator (Thoracic Surgery)</investigator_title>
  </responsible_party>
  <keyword>Lung</keyword>
  <keyword>Cancer</keyword>
  <keyword>Early-Stage</keyword>
  <keyword>Video-assisted Thoracic Surgery</keyword>
  <keyword>VATS</keyword>
  <keyword>SBRT</keyword>
  <keyword>Stereotactic Body Radiation Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

